BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC’s 3rd Largest Position

Exome Asset Management LLC grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 167.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 211,000 shares of the company’s stock after acquiring an additional 132,093 shares during the quarter. BridgeBio Pharma comprises about 3.6% of Exome Asset Management LLC’s investment portfolio, making the stock its 3rd biggest holding. Exome Asset Management LLC’s holdings in BridgeBio Pharma were worth $5,372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in BridgeBio Pharma by 3.8% during the third quarter. Geode Capital Management LLC now owns 3,413,949 shares of the company’s stock valued at $86,936,000 after acquiring an additional 123,540 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in shares of BridgeBio Pharma by 3.5% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,760,457 shares of the company’s stock worth $95,741,000 after purchasing an additional 127,853 shares during the period. Barclays PLC boosted its holdings in shares of BridgeBio Pharma by 31.9% in the third quarter. Barclays PLC now owns 545,008 shares of the company’s stock worth $13,876,000 after buying an additional 131,743 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in BridgeBio Pharma during the third quarter valued at approximately $338,000. Finally, Quarry LP increased its holdings in BridgeBio Pharma by 33.3% during the third quarter. Quarry LP now owns 10,000 shares of the company’s stock valued at $255,000 after buying an additional 2,500 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BBIO has been the subject of several analyst reports. Leerink Partners reduced their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Oppenheimer began coverage on BridgeBio Pharma in a research note on Thursday, October 3rd. They issued a “market perform” rating on the stock. Piper Sandler initiated coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They set an “overweight” rating and a $46.00 price objective for the company. HC Wainwright increased their target price on shares of BridgeBio Pharma from $43.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, Scotiabank lifted their price target on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.69.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at $2,101,116.78. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.66% of the company’s stock.

BridgeBio Pharma Stock Down 0.7 %

Shares of BBIO stock opened at $27.49 on Friday. The stock has a market cap of $5.20 billion, a P/E ratio of -11.41 and a beta of 1.08. The company’s fifty day simple moving average is $25.58 and its two-hundred day simple moving average is $26.12. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $44.32.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.